Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nektar Therapeutics 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 USA

www.nektar.com P: 415-482-5300 F: 415-339-5300

Description:

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.

Key Statistics

Overview:

Market Capitalization, $K 260,738
Enterprise Value, $K 225,458
Shares Outstanding, K 183,618
Annual Sales, $ 90,120 K
Annual Net Income, $ -276,060 K
Last Quarter Sales, $ 23,890 K
Last Quarter Net Income, $ -42,080 K
EBIT, $ -187,180 K
EBITDA, $ -102,860 K
60-Month Beta 0.90
% of Insider Shareholders 3.07%
% of Institutional Shareholders 75.88%
Float, K 177,981
% Float 96.93%
Short Volume Ratio 0.31

Growth:

1-Year Return 74.32%
3-Year Return -92.76%
5-Year Return -95.59%
5-Year Revenue Growth -92.45%
5-Year Earnings Growth -122.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.22 on 03/04/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -0.93
EPS Growth vs. Prev Qtr -15.79%
EPS Growth vs. Prev Year 31.25%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

NKTR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -96.80%
Return-on-Assets % -37.17%
Profit Margin % -306.32%
Debt/Equity 0.00
Price/Sales 2.77
Price/Cash Flow N/A
Price/Book 1.81
Book Value/Share 0.69
Interest Coverage -9.91
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar